-
1
The study evaluated 107 patients with HR-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors and endocrine therapy.
-
2
Median progression-free survival (PFS) was 28.0 months, with 12-month and 24-month PFS rates of 66.4% and 54.1%, respectively.
-
3
Overall survival (OS) rates at 12 and 24 months were 88.8% and 87.8%, with median OS not yet reached during the study.
-
4
Grade 3–4 neutropenia occurred in 58.8% of patients, all managed with dose adjustments, and no cases of febrile neutropenia were reported.
-
5
The findings align with previous clinical trials, indicating favorable efficacy and tolerability of CDK4/6 inhibitors in this patient population.
